REVIVA PHARMACEUTICALS HOLDINGS, INC.

Reviva Pharmaceuticals Holdings, Inc. (Nasdaq: RVPH) is a clinical-stage biopharmaceutical company that entered the public markets through a SPAC business combination and filed its 10-Q quarterly report with the SEC on October 14, 2020, under accession number 0001104659-20-114968. The company focuses on the discovery and development of next-generation therapeutics targeting central nervous system disorders, including schizophrenia and Parkinson's disease dementia, placing it within the healthcare and specialty pharmaceuticals sector. The 2020 filing reflects the company's early post-combination operating period, during which it was advancing its lead pipeline candidates through clinical trials. Visit SpacDesk and sign up for full data, filings history, and deal analytics on RVPH and hundreds of other SPAC-linked companies.